MAP Crosslinker Chirality Regulates Macrophage Polarization Through MD‐2 Engagement and Enables Tunable Immunomodulation Through Novel Peptide Design
Advanced Healthcare Materials · 2026
DOI: 10.1002/adhm.71572 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2026. Verfasst von Alejandra Suarez-Arnedo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Duke University, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Macrophages, Peptides, Lymphocyte Antigen 96, Immunomodulation. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIAID NIH HHS, NIH HHS.
Abstract (Originalsprache)
Microporous annealed particle (MAP) scaffolds are injectable hydrogel biomaterials that promote tissue regeneration by enabling rapid cell infiltration and presenting reparative cues. Previous work showed that substituting L‐ with D‐chiral residues in matrix metalloproteinase (MMP)‐degradable crosslinkers induces adaptive immune‐mediated skin regeneration and balanced macrophage responses in vivo, but the underlying mechanisms remain unclear. Here, we identify myeloid differentiation factor 2 (MD‐2)‐associated TLR4 signaling as a key mechanistic contributor to macrophage polarization driven by crosslinker chirality in MAP scaffolds. Macrophages cultured in D‐chiral MAP (DMAP) scaffolds exhibited reduced iNOS, CD86, and TNF‐α expression and shifted from an M1‐like state toward M0‐like phenotypes compared to L‐chiral MAP (LMAP) and 2D controls. Competitive inhibition with soluble D‐chiral MMP crosslinker peptide (DMMP) partially restored M1 activation, implicating direct peptide–macrophage interactions. Docking and surface plasmon resonance (SPR) analyses revealed higher‐affinity binding of DMMP to MD‐2 relative to L‐chiral peptides. Accordingly, DMAP altered TLR4/MD‐2 trafficking and attenuated endocytosis‐dependent signaling. Engineering a second D‐peptide crosslinker with enhanced MD‐2 affinity (DMMP2) reduced inflammatory markers and promoted regenerative macrophage polarization. Together, these results establish peptide chirality as a tunable design parameter for modulating TLR4/MD‐2 signaling and engineering immunomodulatory MAP scaffolds.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, Duke University, Durham, North Carolina, USA.
- Clinical Science Departments of Neurology and Dermatology, Duke University, Durham, North Carolina, USA.
ORCID-Profile: Alejandra Suarez-Arnedo, Jeremy L Thomas, Pablo Cordero-Alvarado, Amy Kim, April Chavez Espinoza, Koravit Poysungnoen, Tatiana Segura
Förderung
- NIGMS NIH HHS
- NIAID NIH HHS
- NIH HHS
- Duke University Shared Materials Instrumentation Facility
- National Institutes of Health
Zitieren
APA
Suarez-Arnedo, A., Thomas, J. L., Liu, Y., Cordero-Alvarado, P., Kim, A., Espinoza, A. C., Harvey, L., Poysungnoen, K., Lin, F., Ye, Z., & Segura, T. (2026). MAP Crosslinker Chirality Regulates Macrophage Polarization Through MD‐2 Engagement and Enables Tunable Immunomodulation Through Novel Peptide Design. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.71572
Vancouver
Suarez-Arnedo A, Thomas JL, Liu Y, Cordero-Alvarado P, Kim A, Espinoza AC, et al. MAP Crosslinker Chirality Regulates Macrophage Polarization Through MD‐2 Engagement and Enables Tunable Immunomodulation Through Novel Peptide Design. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.71572
BibTeX
@article{SuarezArnedo2026,
author = {Suarez-Arnedo, Alejandra and Thomas, Jeremy L and Liu, Yining and Cordero-Alvarado, Pablo and Kim, Amy and Espinoza, April Chavez and Harvey, Leica and Poysungnoen, Koravit and Lin, Fayanne and Ye, Zhiyou and Segura, Tatiana},
title = {MAP Crosslinker Chirality Regulates Macrophage Polarization Through MD‐2 Engagement and Enables Tunable Immunomodulation Through Novel Peptide Design},
journal = {Advanced Healthcare Materials},
year = {2026},
doi = {10.1002/adhm.71572}
}
EUVIMED